Thursday, April 07, 2022 8:48:54 AM
"This mandate and scope of the project is just the beginning stages of launching more products into major pharmacy retail stores. SOHM's customer will be distributing them to various pharmacy chain stores that include Publix, CVS and Wal-Mart throughout the United States."
"SOHM's customer....will be distributing them....."
What if SOHM's "customer" doesn't do a good job of distributing them?
As SLC-JD has mentioned here several times...we may never know which products or what the "bottles" look like because they are Private Labeled. We also never were given any revenue projections on that deal, so how can we expect them to "hit it big."
No disrespect intended, but all of us would be a little more on the same page as SHMN management if we really "read and comprehended" their communication. Way too much "skim" reading going on here.
Yes, they need to do better, I agree with you on that...
But, we still have a tiny pharma at .0016...and 2022 will be a good trade/investment imo. Not an overnight one.
Hl. Shmn
"SOHM's customer....will be distributing them....."
What if SOHM's "customer" doesn't do a good job of distributing them?
As SLC-JD has mentioned here several times...we may never know which products or what the "bottles" look like because they are Private Labeled. We also never were given any revenue projections on that deal, so how can we expect them to "hit it big."
No disrespect intended, but all of us would be a little more on the same page as SHMN management if we really "read and comprehended" their communication. Way too much "skim" reading going on here.
Yes, they need to do better, I agree with you on that...
But, we still have a tiny pharma at .0016...and 2022 will be a good trade/investment imo. Not an overnight one.
Hl. Shmn
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
